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3 Synthetic Applications of  DNA-based Asym-
metric Michael Reactions 
 
In this chapter, synthetic applications of a DNA-copper conjugate as a supramolecular catalyst for 
asymmetric Michael reactions in water is described. With α,β-unsaturated 2-acylimidazoles as 
substrates, a variety of Michael adducts can be obtained in high yields and enantioselectivities at 
synthetically relevant scales. The products of the Michael reaction can be transformed into γ–
aminobutyric acid (GABA) analogues in a few straightforward steps, demonstrating the potential of 









Conjugate additions belong to the most important and versatile carbon-carbon bond 
forming reactions in chemistry.1 In recent years, enormous progress has been achieved 
in the development of reagents and catalysts for asymmetric 1,4-additions. 2  The 
Michael reaction, the 1,4-addition of a stabilized carbanion to α,β-unsaturated ketones 
or other acceptors, is a valuable and atom-efficient reaction class that can be 
performed in aqueous environments.3 In particular, the asymmetric Michael addition 
to nitroalkenes has been successfully performed using a variety of organocatalysts, 
which activate the nucleophile.4 Excellent yields and enantioselectivities up to >99% 
have been obtained in this case.  
 
A few examples of the asymmetric Lewis-acid catalyzed Michael additions of (a)cyclic 
β-ketoesters to methyl vinyl ketone (MVK) in water have been reported so far (Scheme 
3.1). Using Silver(I)/Tol-BINAP,5 Pd(II)/BINAP6 or Yb(III)/α-amino acids7 as the 
catalysts, the chiral Michael adducts were obtained in good yields and moderate to 
good enantioselectivities (up to 86% ee).  
 
3.1.1 The DNA-based Michael Reaction 
After the successful application of α,β-unsaturated 2-acylimidazoles 3.1 as dienophiles 
in the DNA-based copper-catalyzed asymmetric Diels-Alder reaction, 8 these substrates 
were tested as Michael acceptors as well (Table 3.1).9 The best results were obtained 
with achiral Cu2+-2,2’-dimethylbipyridine (Cu2+-L4) as the DNA-binding Lewis-acid 
catalyst and DNA from salmon testes (st-DNA) as the chiral scaffold. With the 
enolizable nucleophiles dimethylmalonate and nitromethane, 10  the Michael adducts 
were obtained in good to excellent ee with high conversions after 3 days at 5°C.  
 
Scheme 3.1. Asymmetric Michael additions of β-ketoesters to methyl 
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Entry Substrate R Nucleophile Eq. Conv. (%) Ee (%) 
1 3.1a C6H5 CH2(CO2CH3)2 100 full 91 
2   CH3NO2 1000 97 85 
3 3.1b 4-CH3O-C6H4 CH2(CO2CH3)2 100 94 86 
4   CH3NO2 1000 89 82 
5 3.1c 4-Cl-C6H4 CH2(CO2CH3)2 100 75 90 
6   CH3NO2 1000 72 85 
7 3.1d 2-Br-C6H4 CH2(CO2CH3)2 100 full 99 
8   CH3NO2 1000 70 94 
a. Conditions: st-DNA (1.3 mg mL-1), Cu2+-L4 (0.3 mM), substrate (1.0 mM), MOPS 
buffer (20 mM, pH 6.5), 5°C, 3d. 
 
For the DNA-based Diels-Alder reaction, it had already been shown that DNA-based 
asymmetric synthesis could be performed on a semi-preparative scale.8 This was used 
to demonstrate, after derivatization of the Diels-Alder products, that the cycloaddition 
reaction preferentially takes place at the Si face of the dienophile, and the (2S,3S)-
product is formed in excess. The adducts of nitromethane to enones 3.1 are of 
particular interest, since the functional groups of the products are, in principle, readily 
transformed, which opens the way for application of the Michael reaction in the 
asymmetric synthesis of chiral compounds with physiological activity. In this chapter, a 
practical synthetic route to γ–aminobutyric acid (GABA) analogues will be described, 




















3.1.2 γ–Aminobutyric Acid Analogues 
The class of γ–aminobutyric acid (GABA, 3.5, R=H) and its analogues comprises 
important inhibitory neurotransmitters in the mammalian central nervous system.11 
Their activity relies on binding to specific transmembrane receptors in the plasma 
membrane of the synaptic cleft. Several asymmetric syntheses of chiral GABA 
analogues (3.5, R≠H) have been reported, including examples that use catalytic 
asymmetric transformations (up to 92% ee), 12  enantioselective deprotonation of a 
substituted cyclobutanone (98% ee), 13  enzymatic desymmetrization of prochiral 
intermediates or kinetic resolution14  (ees up to 98%) and several diastereoselective 
syntheses.15 In the latter examples, the GABA analogues were generally obtained in 
good yield and ees up to 95%. 
3.2 Results and Discussion 
3.2.1 Scale-up of the Enantioselective DNA-based Michael Reaction 
The DNA-based asymmetric Michael reaction was scaled up to a 1 mmol scale using a 
similar procedure as for the Diels-Alder reaction. To this aim, a reaction volume of 500 
mL was used, and the concentration of the Michael acceptors was increased from 
1mM to 2mM at the same catalyst loading (0.3 mM, 15 mol%; 1 copper complex per 
6.7 basepairs). After extraction of the product, the catalyst solution could be recycled 
at least once without significant loss of activity or enantioselectivity. The results of this 





















3.3, R' = H









Reduction    R' = CH3
Scheme 3.2. The synthesis of GABAs 3.5 and pyrrolidinone analogues 3.6 from 
Michael adducts 3.1. 




Entry Substrate Nucleophile 
Time (d) Conv. (%)b Ee (%)c Yield (%)d 
Anal. scale: 
Ee (%)e 
1 3.1a nitromethane 7 94 83 81 85 
2     82 f   
3 3.1b nitromethane 7 93 82 (90)g 80 82 
4     82 f   
5 3.1c nitromethane 15 45 78 25 85 
6 3.1e dimethylmalonate 6 full 96 80 n.d.h 
a. Conditions: 0.67g st-DNA, 500 mL aqueous MOPS buffer, 20 mM, pH 6.5, 0.15 
mmol Cu2+-L4 (1 copper complex per 6.7 basepairs), 1.0 mmol enone, nitromethane 
(600 eq.) or dimethylmalonate (100 eq.), 5°C; b. determined by 1H NMR spectroscopy; 
c. Determined by chiral HPLC; d. Combined yield after two consecutive runs with 
recycling of the catalyst solution, after column chromatography; e. substrate 
concentration 1.0 mM; f. ee obtained after recycling of the catalyst solution; g. after a 
single recrystallization from ethanol, see text; h. n.d. = not determined. 
 
At the larger reaction scale, substrates 3.1a and 3.1b gave enantioselectivities 
comparable to the reactions at an analytical scale, but the reaction was considerably 
slower. This may be attributed to suboptimal mass transport of the reacting species in 
the larger reaction vessel, considering the heterogeneous mixture of the aqueous 
solution of the substrate and catalyst and nitromethane. The Michael adducts were 
isolated by extraction and purified by column chromatography. Product 3.1b could be 
recrystallized from ethanol for enantiomeric enrichment up to 90% ee, but this resulted 
in an unacceptable loss of product (around 15%). The 4-chlorosubstituted substrate 
3.1c was poorly soluble under the reaction conditions and even after prolonged 
reaction times (15 d), conversion was no more than 45% and adduct 3.2c was isolated 
in poor yield (25%, 44% of unreacted 3.1c was recovered) and moderate ee. The poor 
yield of this reaction made a possible synthesis of baclofen (3.5c, R=4-ClC6H4) using 
the synthetic route outlined in Scheme 3.2 less attractive to pursue. Finally, the 
st-DNA, Cu2+-L4



















Table 3.2. Scale-up of the DNA-based asymmetric Michael addition.a
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addition product of dimethylmalonate to 4-fluorosubstituted enone 3.1e was isolated 
in good yield (80%) and ee (96%), demonstrating the versatility of the DNA-based 
asymmetric synthesis approach. This adduct could possibly be transformed into 
paroxetine in a few steps (Scheme 3.3), although its reported synthesis16 from 3.4d 
proceeds via an achiral intermediate. 
 
3.2.2 Removal of the Imidazole Auxiliary 
The next step in the synthesis of physiologically active molecules is the removal of the 
imidazole group from Michael adducts 3.2. Evans et al. reported a successful approach 
to achieve this;17 by methylation of the imidazole moiety and subsequent attack of a 
nucleophile (water or methanol), the corresponding carboxylic acid or methyl ester can 
be isolated in good yield (Scheme 3.4). 
 
When this strategy was applied to Michael adducts 3.2a-b with water as the 
nucleophile, the desired crude nitroacids 3.3a-b were obtained, but their purification 
from the by-products of the reaction by column chromatography was troublesome and 
isolated yields were low. Therefore, it was decided to use methanol as the nucleophile 











Scheme 3.4. Methylation and removal of the imidazole group.17 
Scheme 3.3. Conceivable formal total synthesis route of paroxetine, 
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after methylation of the imidazole group. This approach results in the corresponding 
nitroesters 3.4, which were easily obtained pure and in good yields by column 
chromatography. Furthermore, nitroesters 3.4 give access to chiral pyrrolidinones (vide 
infra). Methoxy-substituted nitroester 3.4b could be enantiomerically enriched to 98% 
ee by a single recrystallization from ethanol. Saponification with excess lithium 
hydroxide in THF/water 1:1 then yielded the nitroacids 3.3a-b pure in quantitative 
yield (Scheme 3.5). 
 
 
3.2.3 Reduction of the Nitro Group to Give γ–Aminobutyric Acid Analogues 
The final step in the synthesis of GABA analogs from the enantiomerically enriched 
Michael adducts 3.1 is the reduction of the nitro group in 3.3 and 3.4. The latter 
reaction gives an aminoester, which cyclizes in situ to the corresponding chiral 
pyrrolidinone 3.6. Reduction of nitroacids 3.3 gives the γ–aminobutyric acid analogues 
3.5 (Scheme 3.6). Several methods are known for the conversion of a nitro group into 
the corresponding primary amine,18 including reduction with zinc in acetic acid, and 








3.3a, R = H, quant.
3.3b,  R = OCH3, quant.
3.4a
3.4b








3.4a, R = H, 75%, 82% ee
3.4b, R = OCH3, 73%, 82% ee






3.2a, R = H
3.2b, R = OCH3




These procedures were tested on the racemic nitroacids 3.3a-b and nitroester 3.4b, 
and the Pd/C-catalyzed hydrogenation in methanol gave the GABA analogues in good 
yields. Enantiomerically pure (98% ee) pyrrolidinone 3.6 was successfully synthesized in 
90% yield using this approach, starting from methyl ester 3.4b. However, when the 
method was applied in the reduction of the enantiomerically enriched nitroacid 3.3b, 
two products were observed by 1H NMR spectroscopy (around 20% of the impurity). 
ESI and Maldi-TOF mass analysis of the product mixture indicated that an 
unidentified impurity with m/z = 402 had been formed as well as the desired amino 
acid 3.5b. HPLC separation of the components of the mixture of 3.5b (which had 
>98% ee as judged by chiral HPLC analysis) and the side product was unsuccessful, 
and no further attempts were made to obtain the amino acid pure. Hydrolysis of 
pyrrolidinone 3.6 in refluxing 6M aqueous hydrochloric acid was attempted in order to 
obtain 3.5b,19 but the reaction resulted in loss of the methoxy substituent from the 
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aromatic ring, as judged by 1H NMR and mass spectroscopy. Apparently, the applied 
reaction conditions are too harsh for this specific substrate. 
Since catalytic hydrogenation of the nitro group of 3.3b gave an impure product, the 
reduction of the enantiomerically enriched nitroacid 3.3a was performed using zinc in 
acetic acid instead. The corresponding amino acid 3.5a was obtained pure in good 
yield (85 %) and ee (86 %) after purification by cation exchange chromatography to 
remove residual zinc salts from the reduction. 
3.3 Extensions of the DNA-based Michael Reaction 
3.3.1 Trapping of the Enolate Intermediate 
Attempts were also made to trap the intermediate enolate in the Michael addition with 
an electrophile, as in organometallic conjugate additions to enones.20 The use of an 
aldehyde as the electrophile in this tandem reaction would result in chiral compounds 
with three adjacent stereocenters (Scheme 3.7). 
 
In an attempt to trap the intermediate enolate with excess benzaldehyde (10 eq. with 
respect to the substrate) during the addition of dimethylmalonate to enone 3.1a 
(R=C6H5), however, the desired aldol product 3.7 (Nu=CH(CO2CH3), R=R’= C6H5) 
was not observed. Instead, the simple Michael adduct was obtained invariably. 
Apparently, quenching of the enolate by water is faster than its reaction with 
benzaldehyde. An intramolecular reaction could facilitate the trapping event, and 
therefore aldehyde-diester 3.8 was synthesized 21  and used as a nucleophile in the 
Michael addition to 3.1a (Scheme 3.8). However, no conversion was observed, even 
after prolonged reaction times (up to 11 d). This is probably caused by the decreased 
reactivity of deprotonated 3.8 compared to dimethylmalonate, because of steric 
hindrance of the alkyl group. A similar observation was made in the addition of 
dimethyl methylmalonate to enone 3.1a which did not proceed to significant 
conversions after 3d at 20°C. 22  Additionally, the aldehyde may be present as the 
hydrate in aqueous solution, which inhibits the intramolecular addition step as well. 



























3.3.2 Michael Addition to (Z)-enones 
It would be interesting to know the stereochemical outcome of the Michael addition if 
the other isomer of the enone is used as a substrate in the reaction. In this way, the 
opposite enantiomer of the product might be accessible using the same catalyst. 
Therefore attempts were made to synthesize (Z)-3.1a (Scheme 3.9). In the first 
approach, the imidazole group is coupled to (Z)-cinnamic acid, using a procedure by 
Evans et al.17b Alternatively, (Z)-3.1a may be obtained by coupling the imidazole to 
phenylpropiolic acid first, followed by partial hydrogenation. However, both synthetic 
routes yielded (E)-3.1a exclusively (as judged by 1H NMR spectroscopy). Possibly 
(photochemical) cis-trans-isomerization to the more stable (E)-isomer proceeds rather 
easily because of the extended conjugation of the neighboring groups around the 










































3.8 (61%, 2 steps)
Scheme 3.8. Synthesis of aldehyde-diester 3.8 and its attempted use as a nucleophile in
a tandem Michael-aldol reaction. 
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3.4 Conclusions  
In this chapter, the DNA-based asymmetric Michael reaction and its application in the 
synthesis of enantiomerically enriched γ-aminobutyric acid (GABA) analogues was 
described. In a few straightforward steps, (S)-3-phenylGABA and (S)-4-(4-methoxy-
phenyl)-2-pyrrolidinone were synthesized in good yields and good to excellent ee. Due 
to synthetic problems in the last step toward 3-(4-methoxyphenyl)GABA, this amino 
acid was obtained along with ~20% of an unknown impurity. Trapping of the inter-
mediate enolate by an aldehyde was attempted, but no tandem Michael-aldol products 
were obtained. The (Z)-isomer of substrate 3.1a could not successfully be synthesized, 
probably because of its easy transformation into the more stable (E)-isomer. 
3.5 Experimental Section 




was synthesized by adding potassium hydroxide (0.10 
g, 1.8 mmol, 0.22 eq.) to a solution of 4-
fluorobenzaldehyde (0.86 mL, 1.0 g, 8.0 mmol) and 2-
acetyl-1-methylimidazole23 (1.0 g, 8.0 mmol, 1.0 eq.) in 
10 mL of ethanol and stirring the resulting solution overnight, during which the 
product precipitated. After filtration, 3.4d was purified by column chromatography 
(SiO2, hexane / ethyl acetate 3:2, Rf 0.35), giving 3.1e as a colorless powder (1.65g, 7.2 
mmol, 89%), mp. 123.3°C; 1H NMR: δ 8.07 (d, J=34 Hz, 1H), 7.92-7.83 (m, 1H), 7.72 
(d, J=31 Hz, 1H), 7.55 (dd, J=30 Hz, 16, 1H), 7.25 (d, J=11 Hz, 2H) , 7.13-7.08 (m, 
2H), 4.10 (s, 3H) ppm; 13C NMR: δ 180.3, 141.6, 137.3, 133.4, 131.4, 130.5, 129.8, 

































127.7, 124.4, 123.2, 36.5 ppm; MS (EI) for C13H11FN2O: m/z 230.1 (M+), anal. calcd 
for C13H11N2O: C 67.82, H 4.82, N 12.17, found: C 67.92, H 4.82, N 12.22. 
3.5.1 DNA-based Synthesis of Michael Adducts on Preparative Scale 
(General Procedure 1) 
0.67g of st-DNA was dissolved in 333 mL of 30 mM of MOPS buffer (pH 6.5) by 
continuous inversion at 5°C for 24h. Cu(NO3)2-L4 (61 mg, 0.17 mmol, 1 complex per 
6.7 bp) was then added as a solution in 167 mL of water and the catalyst was allowed 
to pre-equilibrate for 3h by continuous inversion at 5°C. Next, 1.0 mmol of the 
Michael acceptor 3.1 was added as a solution in 33 mL of nitromethane (0.61 mmol, 
609 eq.). The resulting emulsion was mixed by continuous inversion for the time 
indicated in Table 3.2 at 5°C, after which it was extracted with 3x 150 mL of diethyl 
ether. The combined organic layers were dried over Na2SO4, filtered and concentrated 
under reduced pressure and the excess of nitromethane was removed in vacuo. Residual 
ether from the aqueous layer containing the DNA/Cu2+-L4 catalyst was removed 
under reduced pressure, and the catalyst solution was recycled for another 2-3 rounds 
for the same reaction. The resulting crude Michael adducts were pooled and purified 
by column chromatography. 
 
(S)-1-(1-methyl-1H-imidazol-2-yl)-4-nitro-3-phenyl-1-butanone 3.2a was 
synthesized from 3.1a (2 x 212mg, 2x 1.0 mmol) and isolated in 81% yield as a white 
solid (440 mg, 1.61 mmol, mp. 93.4°C) after column 
chromatography (hexanes:ethyl acetate 3:2); [α]D25= -48.8° 
(S, c = 4.9, CHCl3); 1H NMR: δ 7.38-7.20 (m, 5H), 7.09 (d, 
J=0.9 Hz, 1H), 6.99 (s, 1H), 4.72 (dd, J=6.8 Hz, 12.5, 1H), 
4.62 (dd, J=8.3 Hz, 12.5, 1H), 4.19 (quint, J=7.2 Hz, 1H), 
3.90 (s, 3H), 3.70 (dd, J=7.2, 17.4 Hz, 1H), 3.46 (dd, J=7.2, 17.4 Hz, 1H) ppm; 13C 
NMR (50 MHz): δ 189.3, 142.7, 139.2, 129.5, 129.1, 127.9, 127.7, 127.6, 80.1, 42.0, 
39.5, 36.3 ppm; MS (CI) for C14H15N3O3: m/z (% base): 274.2 (100, [M+H]+); chiral 
HPLC: Chiralpak AD, heptane/i-PrOH 95/5, flow 1 mL min-1, Tr 28.4 (R), 35.0 (S) 
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(S)-3-(4-methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)-4-nitro-1-butanone 
3.2b was synthesized following general procedure 
1, starting from 3.1b (2x 242mg, 2x 1.0 mmol) and 
isolated in 80% yield as a white solid (485 mg, 1.60 
mmol, mp. 103.6-104.1°C) after column chroma-
tography (hexanes:ethyl acetate 2:1); [α]D20 = -29.6° 
(S, 90% ee,24 c = 1.2, CHCl3); 1H NMR: δ 7.21 (d, J=6.9 Hz, 2H), 7.12 (s, 1H), 7.02 (s, 
1H), 6.83 (d, J=6.9 Hz, 2H), 4.71 (dd, J=6.9, 12.3 Hz, 1H), 4.59 (dd, J=8.3, 12.3 Hz, 
1H), 4.16 (quint, J=7.7 Hz, 1H), 3.94 (s, 3H), 3.76 (s, 3H), 3.69 (dd, J=7.2, 17.4 Hz, 
1H), 3.45 (dd, J=7.2, 17.4 Hz, 1H) ppm; 13C NMR: δ 189.2, 158.9, 130.8, 129.2, 129.2, 
128.5, 127.3, 114.2, 80.1, 55.2, 55.1, 41.8, 38.6 ppm; MS (CI) for C15H17N3O4: m/z (% 
base) 304.2 (100, [M+H]+); anal. calcd. C 59.40, H 5.65, N 13.85, found C 59.22, H 
5.62, N 13.74; chiral HPLC: Chiralpak AD, heptane/i-PrOH 90/10, flow 1 mL min-1, 
Tr 23.3 (R), 28.6 (S) min; ee = 82%.  
 
3-(4-chlorophenyl)-1-(1-methyl-1H-imidazol-2-yl)-4-nitro-1-butanone 3.2c 
was synthesized following general procedure 1, 
starting from 3.1c (2x 247mg, 2x 1.0 mmol) and 
isolated in 25% yield as a colorless oil (229 mg, 0.74 
mmol) after column chromatography (hexanes: ethyl 
acetate 3:2, Rf 0.10), remaining 3.1c was recovered in 
44% yield. For 3.2c, [α]D25 = -25.5° (S, c = 1.09, CHCl3); 1H NMR: δ 7.22-7.31 (m, 4H), 
7.13 (s, 1H), 7.03 (s, 1H), 4.72 (dd, J=12.6, 6.5 Hz, 1H), 4.61 (dd, J=12.6, 8.6 Hz, 1H), 4.21 
(d, J=7.4 Hz, 1H), 3.94 (s, 3H), 3.71 (dd, J=17.4, 7.6 Hz, 1H), 3.46 (dd, J=17.4, 7.0 Hz, 1H) 
ppm; 13C NMR (50MHz): δ 188.7, 142.5, 137.5, 133.6, 129.4, 129.1, 129.0, 127.5, 79.6, 
41.6, 38.7, 36.1 ppm; MS (CI) for C14H14ClN3O3: m/z (% base) 308.1 (100, [M+H]+); 
chiral HPLC: Chiralpak AD, heptane/i-PrOH 95/5, flow 1 mL min-1, Tr 34.6 (minor), 
40.1 (major) min; ee = 82%.  
 
Dimethyl 2-(1-(4-fluorophenyl)-3-(1-methyl-1H-imidazol-2-yl)-3-oxopropyl)-
malonate 3.2d was synthesized following general 
procedure 1, starting from 3.1e (2x 230 mg, 2x 1.0 
mmol) and dimethylmalonate (2x 11.4 mL, 2x 100 
mmol, 100 eq.) and was obtained as a colorless oil 
after column chromatography, combined yield: 580 


















J=19 Hz, 2H), 4.17-4.02 (m, 1H), 3.83-3.67 (m, 2H) 3.65 (s, 3H), 3.32 (d, J=9.6 Hz, 
1H), 3.41 (s, 6H) ppm; 13C NMR: δ 189.9, 168.3 (JC,F=25 Hz), 164.1, 159.3, 143.0, 
136.3, 130.2, 129.6 (JC,F=39 Hz), 127.4, 115.6 (JC,F=34 Hz), 57.6, 52.6, 42.9, 40.0, 36.2 
ppm; MS (EI) for C18H19FN2O5: m/z 362.1 (M+); Chiral HPLC: Chiralpak AD, 
heptane/i-PrOH 85/15, flow 1 mL min-1, Tr 16.2 (minor), 19.0 (major) min; ee = 96%. 
3.5.2 Removal of the Imidazole Group from Michael Adducts 3.225  
(S)-methyl 4-nitro-3-phenylbutanoate 3.4a. To dry and freshly distilled 
acetonitrile (3.5 mL) was added 200mg of 4Å molecular 
sieves and Michael adduct 3.2a (376 mg, 1.38 mmol, final 
concentration 0.4M). The solution was stirred for 1h at 
room temperature under a nitrogen atmosphere, and methyl 
trifluoromethanesulfonate (2.07 mmol, 1.5 eq.) was added via syringe. After stirring for 
an additional 2h, methanol (0.41 mL) and DBU (0.83 mL) was added. Stirring was 
continued overnight, and the reaction was quenched with excess 1M hydrochloric acid. 
After extraction with ethyl acetate (3x 25 mL), the corresponding methyl ester 3.3 was 
isolated as a colorless oil (230 mg, 1.03 mmol, 75%) after column chromatography 
(hexanes/ethyl acetate 5:1) with analytical data as reported;14 [α]D25 = -14° (S, c = 1, 
CHCl3), Lit.14 [α]D25 = +8.7° (R, c = 2, CHCl3); Chiral GC: Chiraldex G-TA, 135°C, He 
flow 1.0 mL min-1, Tr = 51.1 (S), 57.4 (R) min, ee = 82%. 
 
(S)-methyl 3-(4-methoxyphenyl)-4-nitrobutanoate 3.4b was synthesized from 
Michael adduct 3.2b (432 mg, 1,42 mmol) following 
the procedure above. Nitroester 3.3b was isolated in 
73% yield (261 mg, 1.03 mmol) after column 
chromatography (hexanes/ethyl acetate 3:1, Rf 0.29). 
After a single recrystallization from ethanol, the 
product was obtained in 97% ee as colorless needles, mp. 56-57°C. [α]D25 = -11.3° (S, c 
= 1.06, CHCl3); 1H NMR: δ 7.10-7.15 (m, 2H), 6.81- 6.86 (m, 2H), 4.68 (dd, J=12.5, 6.9 
Hz, 1H), 4.57 (dd, J=12.5, 8.1 Hz, 1H), 3.91 (quint, J=7.4 Hz, 1H), 3.74 (s, 3H), 3.59 (s, 
3H), 2.71 (dd, J=7.4, 2.9 Hz, 2H) ppm; 13C NMR: δ 171.0 (s), 159.0 (s), 130.0 (s), 128.2 (d), 
114.2 (d), 79.4 (t), 55.0 (q), 51.7 (q), 39.3 (d), 37.5 (t) ppm; MS (EI) for C12H15NO5: m/z 
(% base) 253.2 (19, [M]+), 206.2 (100), 148.2 (54), 134.1 (58), 91.1 (18); anal. calcd C 
56.91, H 5.97, N 5.53; found C 56.63, H 5.96, N 5.53; chiral HPLC: Chiralcel OD, 
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3.5.3 Hydrolysis of Nitroesters 3.4  
(S)-4-nitro-3-phenylbutanoic acid 3.3a. To an ice cold solution of lithium 
hydroxide monohydrate (214 mg, 5.1 mmol, 5 eq.) in 
THF/water 1:1 (5 mL) was added (S)-3.4a (227 mg, 1.02 
mmol) and the resulting emulsion was stirred vigorously at 
0°C overnight. The reaction mixture was then acidified to pH 
1 by addition of 1M HCl and extracted with 3x 5mL of ethyl 
acetate. The combined organic layers were washed with water, dried over Na2SO4, 
filtered and concentrated, after which nitroacid 3.3a was isolated as an off-white solid 
(214mg, 1.02 mmol, quant.), with analytical data as reported;14 [α]D25 = -17.0° (S, c = 
0.61, MeOH), Lit.14 [α]D25 = -15.2° (S, c = 0.6, MeOH); chiral HPLC: Chiralcel OJ-H, 
0.05% TFA in heptane/i-PrOH 80/20, flow 0.5 mL min-1, Tr 21.7 (S), 29.3 (R) min; ee 
= 83%.  
 
(S)-3-(4-methoxyphenyl)-4-nitrobutanoic acid 3.3b was synthesized from 3.4b 
(57 mg, 0.23 mmol) following the procedure above. 
Nitroacid 3.3b was isolated as a colorless solid (54mg, 
0.23 mmol, quant.); mp 118.4°C; [α]D25 = -18.0° (S, c = 
0.8, CH3OH); 1H NMR (300 MHz): δ 10.75 (br s, 1H), 
7.14 (d, J=8.6 Hz, 2H), 6.86 (d, J=8.6 Hz, 2H), 4.68 (dd, 
J=12.4, 7.2 Hz, 1H), 4.58 (dd, J=12.4, 7.8 Hz, 1H), 3.91 (quint, J=7.4 Hz, 1H), 3.79 (s, 3H), 
2.80 (dd, J=7.3, 2.3 Hz, 2H) ppm; 13C NMR: δ 176.2 (s), 159.3 (s), 129.8 (s), 128.4 (d), 
114.5 (d), 79.5 (t), 55,2 (q), 39.2 (d), 37.4 (t) ppm; MS (ESI) for C11H13NO5: m/z (% base) 
238.4 (18, [M-H]-), 477.4 (100, [2M-H]-); anal. calcd. C 55.23, H 5.48, N 5.86, found 
55.22, H 5.48, N 5.83; chiral HPLC: Chiralcel OD-H, 0.05% TFA in heptane/i-PrOH 
85/15, flow 0.5 mL min-1, Tr 18.2 (R), 21.5 (S) min; ee = 97%.  
3.5.4 Reduction of Nitroacids 3.3 and Nitroester 3.4b 
(S)-4-amino-3-phenylbutanoic acid 3.5a. Nitroacid 3.3a (40 mg, 0.19 mmol) was 
dissolved in acetic acid (2.7 mL) and zinc powder (125 mg, 1.9 
mmol, 10 eq.) was added. The reaction mixture was stirred 
vigorously at room temperature overnight, filtered over a plug 
of celite and the excess of acetic acid was removed in vacuo. 
The amino acid (29 mg, 0.16 mmol, 85 %) was obtained pure 
after ion exchange chromatography on Dowex 50x8 resin (H+ form) eluted with 2.5% 













= +2° (S, c =0.37, H2O, ee = 86%) Lit.15d [α]D23 = -5.8° (R, c = 0.72, H2O); chiral rp-
HPLC: Chirex (D)-Penicillamine, MeOH/2 mM CuSO4 10/90, flow 1.0 mL min-1, Tr 
18.0 (S), 21.6 (R) min; ee 86%. 
 
(S)-4-amino-3-(4-methoxyphenyl)butanoic acid 3.5b (with impurity). 
Nitroacid 3.3b (54 mg, 0.23 mmol) was dissolved in 5 
mL of methanol/water 1:1 and 10% palladium on 
carbon (24 mg, 10 mol% Pd) was added. The suspen-
sion was purged 5 times with a hydrogen/vacuum cycle 
and stirred under 1 bar of hydrogen overnight. The 
reaction mixture was filtered over celite and concentrated in vacuo, after which the 
product mixture was obtained as a colorless solid, dec. at 191°C; 1H NMR of the 
amino acid 3.5b: δ 7.18 (dd, J=6.4, 8.8 Hz, 2H), 6.89 (dd, J=6.4, 8.8 Hz, 2H), 3.70 (s, 
3H), 3.18 (m, 2H), 3.06 (t, J=11.6 Hz, 1H), 2.47 (dd, J=8.0, 14.5 Hz, 1H), 2.37 (dd, 
J=7.9, 14.5 Hz, 1H) ppm; 13C NMR (D2O): δ 179.9, 158.5, 132.1, 129.2, 114.8, 55.5, 
44.4, 42.5, 40.6 ppm; HRMS (ESI) calcd. for C11H16NO3+ ([M+H]+): m/z 210.1125, 
found 210.1105; chiral rp-HPLC: Chirex (D)-Penicillamine, MeOH/2 mM CuSO4 
10/90, flow 1.0 mL min-1, Tr 23.9 (S), 28.3 (R) min; ee >98%; 1H NMR (D2O) of the 
impurity: δ 7.13 (d, J=8.8 Hz, 2H), 6.90 (d, J=8.8 Hz, 2H), 3.81 (s, 3H), 3.41 (m, 2H), 
3.22 (t, J=12.4 Hz, 1H), 2.76 (dd, J=5.0, 16 Hz, 1H), 2.65 (dd, J=7.8, 16 Hz, 1H) ppm; 
MS (ESI): 402.4. 
 
 (S)-4-(4-methoxyphenyl)-2-pyrrolidinone 3.6. Nitroester 3.4b (50 mg, 0.20 
mmol) was dissolved in 5 mL of methanol and 10% 
palladium on carbon (10.5 mg, 5 mol% Pd) was added. The 
suspension was purged 5 times with a hydrogen/vacuum 
cycle and stirred under 1 bar of hydrogen overnight. The 
reaction mixture was filtered over celite, concentrated and 
purified by column chromatography (hexanes: ethyl acetate 1:1 to 1:4), giving 3.6 (34 
mg, 0.18 mmol, 90%) as an off-white solid, with analytical data as reported.26 [α]D25 = 
+27.2° (S, c = 1.16, CH3OH), Lit.26 [α]D25 = -21° (R, 92% ee, c = 1.00, CH3OH); chiral 
HPLC: Chiralpak-AD, heptane/i-PrOH 97/3, flow 1 mL min-1, Tr 40.1 (R), 43.4 (S) 
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